Fmr LLC Sells 3,605,931 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Fmr LLC decreased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 67.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,724,015 shares of the company’s stock after selling 3,605,931 shares during the period. Fmr LLC’s holdings in Fulcrum Therapeutics were worth $6,155,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. National Bank of Canada FI grew its holdings in shares of Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after purchasing an additional 4,000 shares during the last quarter. Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at about $68,000. China Universal Asset Management Co. Ltd. raised its position in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. Renaissance Technologies LLC bought a new stake in Fulcrum Therapeutics during the 2nd quarter worth approximately $82,000. Finally, Intech Investment Management LLC bought a new position in shares of Fulcrum Therapeutics during the third quarter valued at about $62,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Down 5.6 %

Shares of FULC stock opened at $4.03 on Friday. The stock has a market cap of $217.37 million, a PE ratio of -13.00 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $13.70. The company’s fifty day moving average price is $3.50 and its 200-day moving average price is $5.97.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.